SCHEMBL8569914

SCHEMBL8569914

N#Cc1ccnc(N)c1[N+](=O)[O-]

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
HTT P42858 4/20 0.42
KDM4E B2RXH2 2/20 0.42
MITF O75030 1/20 0.42
NOD2 Q9HC29 1/20 0.38
XDH P47989 1/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
RECQL P46063 1/20 0.37
VCAM1 P19320 3/20 0.37
RXFP1 Q9HBX9 1/20 0.36
GRM6 O15303 1/20 0.35
GRIA1 P42261 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA3 P42263 1/20 0.35
GRIA4 P48058 1/20 0.35
MGMT P16455 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31092325 0.79 VCAM1 (0.44) MAPTHTTKDM4EXDHKMT2A
SCHEMBL8559170 0.76 XDH (0.41) MAPTHTTKDM4EXDHLMNA
SCHEMBL3688848 0.76 MAPT (0.47) MAPTHTTKDM4EMITFNOD2
SCHEMBL4756003 0.76 ALDH1A1 (0.35) MAPTHTTKDM4ELMNAKMT2A
SCHEMBL1840418 0.75 MAP4K4 (0.40) MAPTHTTKDM4EMITFNOD2
SCHEMBL8568773 0.74 MAPT (0.46) MAPTHTTKDM4EMITFNOD2
SCHEMBL16919107 0.73 MAPT (0.45) MAPTHTTKDM4EMITFNOD2
SCHEMBL11708343 0.73 MAPT (0.47) MAPTHTTKDM4EMITFNOD2
SCHEMBL11713155 0.73 MAPT (0.45) MAPTHTTKDM4EMITFNOD2
SCHEMBL18474448 0.73 MAPT (0.45) MAPTHTTKDM4EMITFNOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103788086-A Pyridoimidazole compounds and preparation method thereof UNIV CHINA PHARMA 2014-05-14 CN claimed
EP-3752498-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2023-06-28 EP disclosed
US-11608335-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2023-03-21 US disclosed
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2021-02-11 US disclosed
EP-3752498-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2020-12-23 EP disclosed
WO-2019157458-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2019-08-15 WO disclosed
CN-103788086-A Pyridoimidazole compounds and preparation method thereof UNIV CHINA PHARMA 2014-05-14 CN disclosed
EP-0735025-B1 Process for producing aminonitropyridines SUMITOMO CHEMICAL CO (JP) 1998-07-01 EP disclosed
US-5648496-A AMINATION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-15 US disclosed
EP-0735025-A1 Process for producing aminonitropyridines SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-10-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11608335-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 MAPT 3109/4885HTT 684/4885KDM4E 4554/4885
US-20210040087-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 MAPT 3109/4885HTT 684/4885KDM4E 4554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.